Welcome to visit Weimao！
Englishen
Weimao
Englishen
Current location：front page >> healthy

Baili Tianheng announced the Phase II study results of iza-bren combined with osimertinib in the treatment of EGFR mutation NSCLC at WCLC2025

2025-09-19 00:12:00 healthy

Baili Tianheng announced the Phase II study results of iza-bren combined with osimertinib in the treatment of EGFR mutation NSCLC at WCLC2025

Recently, Baili Tianheng announced the Phase II clinical results of its innovative drug iza-bren combined with osimertinib (osimertinib) in the treatment of EGFR mutant non-small cell lung cancer (NSCLC) at the 2025 World Lung Cancer Conference (WCLC). This study has attracted widespread attention from the industry and provides new treatment options for patients with advanced EGFR mutation lung cancer.

Research background and design

Baili Tianheng announced the Phase II study results of iza-bren combined with osimertinib in the treatment of EGFR mutation NSCLC at WCLC2025

EGFR mutations are an important driver gene for NSCLC. Although third-generation EGFR-TKI osimertinib has become the first-line standard treatment, drug resistance remains a clinical challenge. Iza-bren is a novel targeted drug that delays resistance by inhibiting specific signaling pathways. This study aims to evaluate the safety and effectiveness of combination therapy.

The study included patients with EGFR mutation NSCLC who progressed after osimertinib treatment, which were divided into the combination group (iza-bren + osimertinib) and the single-agent group (osimertinib). The primary endpoint was progression-free survival (PFS), and the secondary endpoints included objective response rate (ORR) and safety.

Research groupingNumber of patientsMedian PFS (month)ORR (%)
Joint group (iza-bren + osimertinib)859.748.2
Single-agent group (oxitinib)835.322.9

Key data results

The median PFS in the combined group was significantly better than that in the single-agent group (9.7 months vs 5.3 months, HR = 0.52, p < 0.001), and the ORR was also significantly improved (48.2% vs 22.9%). Subgroup analysis showed that combination therapy was effective for different EGFR mutation subtypes (such as 19del and L858R).

Adverse reactions (≥3)Combined group incidence (%)Incidence rate of single-agent group (%)
rash15.38.4
diarrhea12.96.0
Hepatic abnormalities9.43.6

Security Analysis

The incidence of adverse reactions in the combined group was slightly higher, but most of them were controllable level 1-2 events. Grade 3 rash (15.3% vs 8.4%) and diarrhea (12.9% vs 6.0%) were the main differences, and no treatment-related deaths occurred.

Expert evaluation and prospects

WCLC experts pointed out that the study provides a breakthrough plan for osimertinib-resistant patients, with PFS nearly doubled in combination therapy and acceptable safety. Baili Tianheng said that the Phase III global multi-center study has been launched and will further verify the efficacy.

Industry impact and patient benefits

If the Phase III study is successful, iza-bren is expected to become the first targeted drug approved for combined treatment after EGFR-TKI resistance, and rewrite clinical guidelines. Patients can expect longer survival benefits and less chemotherapy needs.

(Note: The data in this article is based on the results released by WCLC2025, and actual clinical applications must be subject to regulatory approval.)

Metallurgical Microscope

Next article
  • My stomach hurts no matter what I eat.

    check the details
    My stomach hurts no matter what I eat.
    Your stomach hurts no matter what you eat? Analysis of hot health topics in the past 10 daysIn the past 10 days, discussions about "gastrointestinal discomfort" have soared on social media and health forums, with many netizens reporting that "everything they eat makes their stomach hurt." From dietary taboos to potential illnesses, the phenomenon has sparked widespread concern. The following are hot topics and struct
    2026-01-26 healthy
  • What kind of tea can you drink to eliminate kidney stones?

    check the details
    What kind of tea can you drink to eliminate kidney stones?
    What kind of tea can you drink to get rid of kidney stones? Analysis of hot topics on the Internet in 10 daysRecently, dietary treatment methods for kidney stones have become a hot topic in the health field, especially the effect of tea in removing stones, which has triggered widespread discussion. This article will combine the hot content on the Internet in the past 10 days to sort out the scientific basis and pract
    2026-01-23 healthy
  • What causes male spermatorrhea

    check the details
    What causes male spermatorrhea
    What causes male spermatorrheaNocturnal emissions are the involuntary discharge of semen during sleep, which usually occurs in adolescent and adult men. Although this is a normal physiological phenomenon, frequent nocturnal emissions may be related to a variety of factors. This article will combine the hot topics and hot content on the Internet in the past 10 days, analyze the causes of spermatorrhea from the aspects
    2026-01-21 healthy
  • What should I not eat if my throat is sore and swollen?

    check the details
    What should I not eat if my throat is sore and swollen?
    What can't you eat if you have a sore throat? List of 10 taboo foods and scientific adviceRecently, "pharyngitis" and "swollen and sore throat" have become hot topics on social platforms. Especially with the change of seasons and the high incidence of influenza, related searches have surged. This article combines the hot health content on the Internet in the past 10 days to sort out a list of dietary taboos during th
    2026-01-18 healthy
Latest articles
Recommended articles
Reading rankings
Friendly links
Dividing line